Breast cancer screening

Last updated
Breast cancer screening
Mammogram.jpg
A woman having a mammogram

Breast cancer screening is the medical screening of asymptomatic, apparently healthy women for breast cancer in an attempt to achieve an earlier diagnosis. The assumption is that early detection will improve outcomes. A number of screening tests have been employed, including clinical and self breast exams, mammography, genetic screening, ultrasound, and magnetic resonance imaging.

Contents

A clinical or self breast exam involves feeling the breast for lumps or other abnormalities. Medical evidence, however, does not support its use in women with a typical risk for breast cancer. [1]

Universal screening with mammography is controversial as it may not reduce all-cause mortality and may cause harms through unnecessary treatments and medical procedures. Many national organizations recommend it for most older women. The United States Preventive Services Task Force recommends screening mammography in women at normal risk for breast cancer, every two years between the ages of 50 and 74. [2] Other positions vary from no screening to starting at age 40 and screening yearly. [3] [4] Several tools are available to help target breast cancer screening to older women with longer life expectancies. [5] Similar imaging studies can be performed with magnetic resonance imaging but evidence is lacking. [2] [6]

Earlier, more aggressive, and more frequent screening is recommended for women at particularly high risk of developing breast cancer, such as those with a confirmed BRCA mutation, those who have previously had breast cancer, and those with a strong family history of breast and ovarian cancer.

Abnormal findings on screening are further investigated by surgically removing a piece of the suspicious lumps (biopsy) to examine them under the microscope. Ultrasound may be used to guide the biopsy needle during the procedure. Magnetic resonance imaging is used to guide treatment, but is not an established screening method for healthy women.

Breast exam

A pictorial example of breast self-examination in six steps. Steps 1-3 involve visual inspection of the breasts with the arms in different positions. Step 4 is palpation of the breast. Step 5 is palpation of the nipple. Step 6 is palpation of the breast while lying down. Breast self-exam NCI visuals online.jpg
A pictorial example of breast self-examination in six steps. Steps 1-3 involve visual inspection of the breasts with the arms in different positions. Step 4 is palpation of the breast. Step 5 is palpation of the nipple. Step 6 is palpation of the breast while lying down.

Breast examinations (either clinical breast exams (CBE) by a health care provider or by self exams) are highly debated. Like mammography and other screening methods, breast examinations produce false positive results, contributing to harm. The use of screening in women without symptoms and at low risk is thus controversial. [7]

A 2003 Cochrane review found screening by breast self-examination is not associated with lower death rates among women who report performing breast self-examination and does, like other breast cancer screening methods, increase harms, in terms of increased numbers of benign lesions identified and an increased number of biopsies performed. [1] They conclude "at present, breast self-examination cannot be recommended". [1] Another study done by the National Breast Cancer Foundation states that 8 out of 10 lumps found are noncancerous.

On the other hand, Lillie D. Shockney, a Professor from Johns Hopkins University states, ‘Forty percent of diagnosed breast cancers are detected by women who feel a lump, so establishing a regular breast self-exam is very important.’ [8] [1]

There are different tactics on how to go about examining one's breasts. Doctors suggest that you use the pads of your three middle fingers and move them in circular motions starting at the center of the breast and continuing out into the armpit area. Apply different amounts of pressure while conducting the exam. Any lumps, thickenings, hardened knots, or any other breast changes should be brought to the attention of your healthcare provider. It is also important to look for changes in color or shape, nipple discharge, dimpling, and swelling. [9]

Mammography

Mammography is a common screening method, since it is relatively fast and widely available in developed countries. Mammography is a type of radiography used on the breasts. It is typically used for two purposes: to aid in the diagnosis of a woman who is experiencing symptoms or has been called back for follow-up views (called diagnostic mammography), and for medical screening of apparently healthy women (called screening mammography). [10]

Mammography is not very useful in finding breast tumors in dense breast tissue characteristic of women under 40 years. [11] [12] In women over 50 without dense breasts, breast cancers detected by screening mammography are usually smaller and less aggressive than those detected by patients or doctors as a breast lump. This is because the most aggressive breast cancers are found in dense breast tissue, which mammograms perform poorly on. [11] The European Commission's Scientific Advice Mechanism recommends that MRI scans are used in place of mammography for women with dense breast tissue. [6]

The presumption was that by detecting cancer in an earlier stage, women will be more likely to be cured by treatment. This assertion, however, has been challenged by recent reviews which have found the significance of these net benefits to be lacking for women at average risk of dying from breast cancer.[ citation needed ]

Mechanism

Normal (left) versus cancerous (right) mammography image. Mammo breast cancer.jpg
Normal (left) versus cancerous (right) mammography image.

Screening mammography is usually recommended to women who are most likely to develop breast cancer. In general, this includes women who have risk factors such as having a personal or family history of breast cancer or being older women, but not being frail elderly women, who are unlikely to benefit from treatment.

Women who agree to be screened have their breasts X-rayed on a specialized X-ray machine. This exposes the woman's breasts to a small amount of ionizing radiation, which has a very small, but non-zero, chance of causing cancer.

The X-ray image, called a radiograph, is sent to a physician who specializes in interpreting these images, called a radiologist . The image may be on plain photographic film or digital mammography on a computer screen; despite the much higher cost of the digital systems, the two methods are generally considered equally effective. The equipment may use a computer-aided diagnosis (CAD) system.

There is considerable variation in interpreting the images; the same image may be declared normal by one radiologist and suspicious by another. It can be helpful to compare the images to any previously taken images, as changes over time may be significant.

If suspicious signs are identified in the image, then the woman is usually recalled for a second mammogram, sometimes after waiting six months to see whether the spot is growing, or a biopsy of the breast. [13] Most of these will prove to be false positives, resulting in sometimes debilitating anxiety over nothing. Most women recalled will undergo additional imaging only, without any further intervention. Recall rates are higher in the U.S. than in the UK. [14]

Effectiveness

On balance, screening mammography in older women increases medical treatment and saves a small number of lives. [3] Usually, it has no effect on the outcome of any breast cancer that it detects. Screening targeted towards women with above-average risk produces more benefit than screening of women at average or low risk for breast cancer.

A 2013 Cochrane review estimated that mammography in women between 50 and 75 years old results in a relative decreased risk of death from breast cancer of 15% and an absolute risk reduction of 0.05%. [3] However, when the analysis included only the least biased trials, women who had regular screening mammograms were just as likely to die from all causes, and just as likely to die specifically from breast cancer, as women who did not. The size of effect might be less in real life compared with the results in randomized controlled trials due to factors such as increased self-selection rate among women concerned and increased effectiveness of adjuvant therapies. [15] The Nordic Cochrane Collection (2012) reviews said that advances in diagnosis and treatment might make mammography screening less effective at saving lives today. They concluded that screening is "no longer effective" at preventing deaths and "it therefore no longer seems reasonable to attend" for breast cancer screening at any age, and warn of misleading information on the internet. [16] The review also concluded that "half or more" of cancers detected with mammography would have disappeared spontaneously without treatment. They found that most of the earliest cell changes found by mammography screening (carcinoma in situ) should be left alone because these changes would not have progressed into invasive cancer. [16]

The accidental harm from screening mammography has been underestimated. Women who have mammograms end up with increased surgeries, chemotherapy, radiotherapy and other potentially procedures resulting from the over-detection of harmless lumps. Many women will experience important psychological distress for many months because of false positive findings. [3] Half of suspicious findings will not become dangerous or will disappear over time. [3] Consequently, the value of routine mammography in women at low or average risk is controversial. [3] With unnecessary treatment of ten women for every one woman whose life was prolonged, the authors concluded that routine mammography may do more harm than good. [3] If 1,000 women in their 50s are screened every year for ten years, the following outcomes are considered typical in the developed world: [17]

The outcomes are worse for women in their 20s, 30s, and 40s, as they are far less likely to have a life-threatening breast cancer, and more likely to have dense breasts that make interpreting the mammogram more difficult. Among women in their 60s, who have a somewhat higher rate of breast cancer, the proportion of positive outcomes to harms are better: [19]

Mammography is not generally considered as an effective screening technique for women at average or low risk of developing cancer who are less than 50 years old. For normal-risk women 40 to 49 years of age, the risks of mammography outweigh the benefits, [20] and the US Preventive Services Task Force says that the evidence in favor of routine screening of women under the age of 50 is "weak". [21] Part of the difficulty in interpreting mammograms in younger women stems from breast density. Radiographically, a dense breast has a preponderance of glandular tissue, and younger age or estrogen hormone replacement therapy contribute to mammographic breast density. After menopause, the breast glandular tissue gradually is replaced by fatty tissue, making mammographic interpretation much more accurate.

Recommendations

Recommendations to attend to mammography screening vary across countries and organizations, with the most common difference being the age at which screening should begin, and how frequently or if it should be performed, among women at typical risk for developing breast cancer.

In England, all women were invited for screening once every three years beginning at age 50,. [22] There is a trial in progress to assess the risks and benefits of offering screening to women aged 47 to 49. Some other organizations recommend mammograms begin as early as age 40 in normal-risk women, and take place more frequently, up to once each year. Women at higher risk may benefit from earlier or more frequent screening. Women with one or more first-degree relatives (mother, sister, daughter) with premenopausal breast cancer often begin screening at an earlier age, perhaps at an age 10 years younger than the age when the relative was diagnosed with breast cancer.

As of 2009 the United States Preventive Services Task Force recommends that women over the age of 50 receive mammography once every two years. [21]

In March 2022, the European Commission's Scientific Advice Mechanism recommended extending screening to women in their mid-40s. [6]

The Cochrane Collaboration (2013) states that the best quality evidence neither demonstrates a reduction in either cancer specific, nor a reduction in all-cause mortality from screening mammography. [3] When less rigorous trials are added to the analysis there is a reduction in breast cancer specific mortality of 0.05% (a relative decrease of 15%). [3] Screening results in a 30% increase in rates of over-diagnosis and over-treatment, resulting in the view that it is not clear whether mammography screening does more good or harm. [3] On their Web site, Cochrane currently concludes that, due to recent improvements in breast cancer treatment, and the risks of false positives from breast cancer screening leading to unnecessary treatment, "it therefore no longer seems reasonable to attend for breast cancer screening" at any age. [16] [23]

Breast density

Two mammograms of normal dense breasts. Mammogram showing normal dense breasts.jpg
Two mammograms of normal dense breasts.

Breasts are made up of breast tissue, connective tissue, and adipose (fat) tissue. The amount of each of the three types of tissue varies from person to person. Breast density is a measurement of relative amounts of these three tissues in breasts, as determined by their appearance on an X-ray image. Breast and connective tissues are radiographically denser (they produce a brighter white on an X-ray) than adipose tissue on a mammogram, so a person with more breast tissue and/or more connective tissue is said to have greater breast density. Breast density is assessed by mammography and expressed as a percentage of the mammogram occupied by radiologically dense tissue (percent mammographic density or PMD). [24] About half of middle-aged women have dense breasts, and breasts generally become less dense as they age. Higher breast density is an independent risk factor for breast cancer. Further, breast cancers are difficult to detect through mammograms in women with high breast density because most cancers and dense breast tissues have a similar appearance on a mammogram. As a result, higher breast density is associated with a higher rate of false negatives (missed cancers). [25] Because of the importance of breast density as a risk indicator and as a measure of diagnostic accuracy, automated methods have been developed to facilitate assessment and reporting for mammography, [26] [27] and tomosynthesis. [28]

Health programs

United States

In 2005, about 68% of all U.S. women age 40–64 had a mammogram in the past two years (75% of women with private health insurance, 56% of women with Medicaid insurance, 38% of currently uninsured women, and 33% of women uninsured for more than 12 months). [29] All U.S. states except Utah require private health insurance plans and Medicaid to pay for breast cancer screening. [30] As of 1998, Medicare (available to those aged 65 or older or who have been on Social Security Disability Insurance for over 2 years) pays for annual screening mammography in women aged 40 or older.

Canada

Three out of twelve (3/12) breast cancer screening programs in Canada offer clinical breast examinations. [31] All twelve offer screening mammography every two years for women aged 50–69, while nine out of twelve (9/12) offer screening mammography for women aged 40–49. [31] In 2003, about 61% of women aged 50–69 in Canada reported having had a mammogram within the past two years. [32]

United Kingdom

The UK's NHS Breast Screening Programme, the first of its kind in the world, began in 1988 and achieved national coverage in the mid-1990s. It provides free breast cancer screening mammography every three years for all women in the UK aged from 50 and up to their 71st birthday. The NHS Breast Screening Programme is supporting a research study trial to assess the risks (i.e. the chances of being diagnosed and treated for a non-life-threatening cancer) and benefits (i.e. the chances of saving life) in women aged 47 to 49 and 71 to 73 (Public Health England 2017).

As of 2006, about 76% of women aged 53–64 resident in England had been screened at least once in the previous three years. [33] However a 2016 UK-based study has also highlighted that the uptake of breast cancer screening among women living with severe mental illness (SMI) is lower than patients of the same age in the same population, without SMI. [34] In Northern Ireland women with mental health problems were shown to be less likely to attend screening for breast cancer, than women without. The lower attendance numbers remained the same even when marital status and social deprivation were taken into account. [35] [36] People from minority ethnic communities are also less likely to attend cancer screening. In the UK, women of South Asian heritage are the least likely to attend breast cancer screening. [37] [38] [39]

After information technology problems affected the recall system in England an internal inquiry by Public Health England and an independent inquiry were established and the National Audit Office started an investigation. [40]

Australia

The Australian national breast screening program, BreastScreen Australia, was commenced in the early 1990s and invites women aged 50–74 to screening every 2 years. No routine clinical examination is performed, and the cost of screening is free to the point of diagnosis.

Singapore

The Singapore national breast screening program, BreastScreen Singapore, started in 2002. It is the only publicly funded national breast screening program in Asia and enrolls women aged 50–64 for screening every two years. Like the Australian system, no clinical examination is performed routinely. Unlike most national screening systems, however, clients have to pay half of the cost of the screening mammogram; this is in line with the Singapore health system's core principle of co-payment for all health services.

Criticisms

Most women significantly overestimate both their own risk of dying from breast cancer and the effect screening mammography could have on it. [41] Some researchers worry that if women correctly understood that screening programs offer a small, but statistically significant benefit, more women would refuse to participate. [41]

The contribution of mammography to the early diagnosis of cancer is controversial, and for those found with benign lesions, mammography can create a high psychological and financial cost. Most women participating in mammography screening programs accept the risk of false positive recall, and the majority do not find it very distressing.[ citation needed ] Many patients find the recall very frightening, and are intensely relieved to discover that it was a false positive, as about 90% of women do. [42]

A major effect of routine breast screening is to greatly increase the rate of early breast cancer detection, in particular for non-invasive ductal carcinoma in situ (DCIS), sometimes called "pre-breast cancer", which almost never forms a lump and which generally cannot be detected except through mammography. While this ability to detect such very early breast malignancies is at the heart of claims that screening mammography can improve survival from breast cancer, it is also controversial. This is because a very large proportion of such cases will not progress to kill the patient, and thus mammography cannot be genuinely claimed to have saved any lives in such cases; in fact, it would lead to increased sickness and unnecessary surgery for such patients.

Consequently, finding and treating many cases of DCIS represents overdiagnosis and overtreatment. Treatment is given to all women with DCIS because it is currently impossible to predict which patients with DCIS will have an indolent, non-fatal course, and which few will inevitably progress to invasive cancer and premature death if left untreated. Consequently, all patients with DCIS are treated in much the same way, with at least wide local excision, and sometimes mastectomy if the DCIS is very extensive. The cure rate for DCIS if treated appropriately is extremely high, partly because the majority of DCIS cases were harmless in the first place.

The phenomenon of finding pre-invasive malignancy or nonmalignant benign disease is commonplace in all forms of cancer screening, including pap smears for cervical cancer, fecal occult blood testing for colon cancer, and prostate-specific antigen testing for prostate cancer. All of these tests have the potential to detect asymptomatic cancers, and all of them have a high rate of false positives and lead to invasive procedures that are unlikely to benefit the patient.

Risk-based screening

Risk-based screening uses risk assessment of a woman's five-year and lifetime risk of developing breast cancer to issue personalized screening recommendations of when to start, stop, and how often to screen. [43] In general, women with low risk are recommended to screen less frequently, while screening is intensified in those at high risk. The NCI (National Cancer Institute) provides a free breast cancer risk assessment tool online that utilizes the Gail Model to predict risk of developing invasive breast cancer based on a woman's personal information. [44] This tool has been found to underestimate the risk of breast cancer in non-white women. [44] The hypothesis is that focusing screening on women most likely to develop invasive breast cancer will reduce overdiagnosis and overtreatment. The first clinical trial testing the safety and efficacy of risk-based screening compared to annual screening, the Wisdom Study, is under way in California (ClinicalTrials.gov Identifier: NCT02620852)

Molecular breast imaging

Molecular breast imaging is a nuclear medicine technique that is currently under study. It shows promising results for imaging people with dense breast tissue and may have accuracies comparable to MRI. [45] It may be better than mammography in some people with dense breast tissue, detecting two to three times more cancers in this population. [45] It however carries a greater risk of radiation damage making it inappropriate for general breast cancer screening. [46] It is possible to reduce the dose of radiation used. [47]

An earlier alternative technique suited to dense breast tissue, scintimammography is now not recommended by the American Cancer Society, which states, "This test cannot show whether an abnormal area is cancer as accurately as a mammogram, and it's not used as a screening test. Some radiologists believe this test may be helpful in looking at suspicious areas found by mammogram. But the exact role of scintimammography is still unclear." [48]

Ultrasonography

Medical ultrasonography is a diagnostic aid to mammography. Adding ultrasonography testing for women with dense breast tissue increases the detection of breast cancer, but also increases false positives. [49] [50]

Magnetic resonance imaging

Magnetic resonance imaging (MRI) has been shown to detect cancers not visible on mammograms. The chief strength of breast MRI is its very high negative predictive value. A negative MRI can rule out the presence of cancer to a high degree of certainty, making it an excellent tool for screening in patients at high genetic risk or radiographically dense breasts, and for pre-treatment staging where the extent of disease is difficult to determine on mammography and ultrasound. MRI can diagnose benign proliferative change, fibroadenomas, and other common benign findings at a glance, often eliminating the need for costly and unnecessary biopsies or surgical procedures. The spatial and temporal resolution of breast MRI has increased markedly in recent years, making it possible to detect or rule out the presence of small in situ cancers, including ductal carcinoma in situ.

Despite the aids provided from MRIs, there are some disadvantages. For example, although it is 27–36% more sensitive, it has been claimed to be less specific than mammography. [51] As a result, MRI studies may have up to 30% more false positives, which may have undesirable financial and psychological costs on the patient. Also, MRI procedures are expensive and include an intravenous injection of a gadolinium contrast, which has been implicated in a rare reaction called nephrogenic systemic fibrosis (NFS). [51] Although NSF is uncommon, other patients with a history of renal failure/disease would not be able to undergo an MRI scan. Breast MRI is not recommended for screening all breast cancer patients, yet limited to patients with high risk of developing breast cancer that may have high familial risk or mutations in BCRA1/2 genes. [52] Breast MRI is not a perfect tool despite its increased sensitivity for detecting breast cancer masses when compared to mammography. This due to the ability of MRIs to miss some cancers that would have been detected with conventional mammography. As a result, MRI screening for breast cancer is most effective as a combination with other tests and for certain breast cancer patients. [53] [52] In contrast, the use of MRIs are often limiting to patients with any body metal integration such as patients with tattoos, pacemakers, tissue expanders, and so on.

Proposed indications for using MRI for screening include: [54]

In addition, breast MRI may be helpful for screening in women who have had breast augmentation procedures involving intramammary injections of various foreign substances that may mask the appearances of breast cancer on mammography and/or ultrasound. These substances include silicone oil and polyacrylamide gel.

BRCA testing

Genetic testing does not detect cancers, but may reveal a propensity to develop cancer. Women who are known to have a higher risk of developing breast cancer usually undertake more aggressive screening programs. However, research has shown that genetic screening needs to be adapted for use in women from different ethnic groups. A study in the UK found that two established risk scores – called SNP18 and SNP143 – are inaccurate and exaggerate risk in Black, Asian, mixed-race and Ashkenazi Jewish women. [55] [56]

A clinical practice guideline by the US Preventive Services Task Force recommends against routine referral for genetic counseling or routine testing for BRCA mutations, on fair evidence that the harms outweigh the benefits. [57] It also encourages a referral for counseling and testing in women who have a family history that indicates they have an increased risk of a BRCA mutation, on fair evidence of benefit. [57] About 2% of American women have family histories that indicate an increased risk of having a medically significant BRCA mutation. [57]

Other

Related Research Articles

<span class="mw-page-title-main">Breast cancer</span> Cancer that originates in mammary glands

Breast cancer is a cancer that develops from breast tissue. Signs of breast cancer may include a lump in the breast, a change in breast shape, dimpling of the skin, milk rejection, fluid coming from the nipple, a newly inverted nipple, or a red or scaly patch of skin. In those with distant spread of the disease, there may be bone pain, swollen lymph nodes, shortness of breath, or yellow skin.

<span class="mw-page-title-main">Mammography</span> Process of using low-energy X-rays to examine the human breast for diagnosis and screening

Mammography is the process of using low-energy X-rays to examine the human breast for diagnosis and screening. The goal of mammography is the early detection of breast cancer, typically through detection of characteristic masses or microcalcifications.

<span class="mw-page-title-main">Breast self-examination</span> Physical and visual inspection of ones own breasts

Breast self-examination (BSE) is a screening method used in an attempt to detect early breast cancer. The method involves the woman herself looking at and feeling each breast for possible lumps, distortions or swelling.

Technetium (<sup>99m</sup>Tc) sestamibi Pharmaceutical drug

Technetium (99mTc) sestamibi (INN) is a pharmaceutical agent used in nuclear medicine imaging. The drug is a coordination complex consisting of the radioisotope technetium-99m bound to six (sesta=6) methoxyisobutylisonitrile (MIBI) ligands. The anion is not defined. The generic drug became available late September 2008. A scan of a patient using MIBI is commonly known as a "MIBI scan".

Computed tomography laser mammography (CTLM) is the trademark of Imaging Diagnostic Systems, Inc. for its optical tomographic technique for female breast imaging.

Ductal carcinoma <i>in situ</i> Pre-cancerous breast lesion

Ductal carcinoma in situ (DCIS), also known as intraductal carcinoma, is a pre-cancerous or non-invasive cancerous lesion of the breast. DCIS is classified as Stage 0. It rarely produces symptoms or a breast lump that can be felt, typically being detected through screening mammography. It has been diagnosed in a significant percentage of men.

<span class="mw-page-title-main">Fibrocystic breast changes</span> Medical condition

Fibrocystic breast changes is a condition of the breasts where there may be pain, breast cysts, and breast masses. The breasts may be described as "lumpy" or "doughy". Symptoms may worsen during certain parts of the menstrual cycle due to hormonal stimulation. These are normal breast changes, not associated with cancer.

The Breast Imaging-Reporting and Data System (BI-RADS) is a quality assurance tool originally designed for use with mammography. The system is a collaborative effort of many health groups but is published and trademarked by the American College of Radiology (ACR).

<span class="mw-page-title-main">Breast cyst</span> Medical condition

A breast cyst is a cyst, a fluid-filled sac, within the breast. One breast can have one or more cysts. They are often described as round or oval lumps with distinct edges. In texture, a breast cyst usually feels like a soft grape or a water-filled balloon, but sometimes a breast cyst feels firm.

<span class="mw-page-title-main">Molecular breast imaging</span>

Molecular breast imaging (MBI), also known as scintimammography, is a type of breast imaging test that is used to detect cancer cells in breast tissue of individuals who have had abnormal mammograms, especially for those who have dense breast tissue, post-operative scar tissue or breast implants.

<span class="mw-page-title-main">Cancer screening</span> Method to detect cancer

The objective of cancer screening is to detect cancer before symptoms appear, involving various methods such as blood tests, urine tests, DNA tests, and medical imaging. The purpose of screening is early cancer detection, to make the cancer easier to treat and extending life expectancy. In 2019, cancer was the second leading cause of death globally; more recent data is pending due to the COVID-19 pandemic.

<span class="mw-page-title-main">Breast ultrasound</span> Type of medical imaging

Breast ultrasound is a medical imaging technique that uses medical ultrasonography to perform imaging of the breast. It can be performed for either diagnostic or screening purposes and can be used with or without a mammogram. In particular, breast ultrasound may be useful for younger women who have denser fibrous breast tissue that may make mammograms more challenging to interpret.

Thomas M. Kolb is an American radiologist specializing in the detection and diagnosis of breast cancer in young, predominantly high-risk premenopausal women. He has served as an assistant clinical professor of Radiology at Columbia University College of Physicians and Surgeons from 1994–2010. Kolb is double board certified, having received his training in pediatrics at the Albert Einstein College of Medicine in Bronx, New York, and in diagnostic radiology at the Columbia-Presbyterian Medical Center in New York.

<span class="mw-page-title-main">Breast biopsy</span> Surgical diagnostic procedure for breast tumours

A breast biopsy is usually done after a suspicious lesion is discovered on either mammography or ultrasound to get tissue for pathological diagnosis. Several methods for a breast biopsy now exist. The most appropriate method of biopsy for a patient depends upon a variety of factors, including the size, location, appearance and characteristics of the abnormality. The different types of breast biopsies include fine-needle aspiration (FNA), vacuum-assisted biopsy, core needle biopsy, and surgical excision biopsy. Breast biopsies can be done utilizing ultrasound, MRI or a stereotactic biopsy imaging guidance. Vacuum assisted biopsies are typically done using stereotactic techniques when the suspicious lesion can only be seen on mammography. On average, 5–10 biopsies of a suspicious breast lesion will lead to the diagnosis of one case of breast cancer. Needle biopsies have largely replaced open surgical biopsies in the initial assessment of imaging as well as palpable abnormalities in the breast.

<span class="mw-page-title-main">Triple test score</span>

The triple test score is a diagnostic tool for examining potentially cancerous breasts. Diagnostic accuracy of the triple test score is nearly 100%. Scoring includes using the procedures of physical examination, mammography and needle biopsy. If the results of a triple test score are greater than five, an excisional biopsy is indicated.

Dynamic angiothermography (DATG) is a technique for the diagnosis of breast cancer. This technique, though springing from the previous conception of thermography, is based on a completely different principle. DATG records the temperature variations linked to the vascular changes in the breast due to angiogenesis. The presence, change, and growth of tumors and lesions in breast tissue change the vascular network in the breast. Consequently, through measuring the vascular structure over time, DATG effectively monitors the change in breast tissue due to tumors and lesions. It is currently used in combination with other techniques for diagnosis of breast cancer. This diagnostic method is a low-cost one compared with other techniques.

A well-woman examination is an exam offered to women to review elements of their reproductive health. The exam includes a breast examination, a pelvic examination and a Pap smear but may include other procedures. Hospitals employ strict policies relating to the provision of consent by the patient, the availability of chaperones at the examination, and the absence of other parties.

<span class="mw-page-title-main">Breast imaging</span>

In medicine, breast imaging is a sub-speciality of diagnostic radiology that involves imaging of the breasts for screening or diagnostic purposes. There are various methods of breast imaging using a variety of technologies as described in detail below. Traditional screening and diagnostic mammography uses x-ray technology and has been the mainstay of breast imaging for many decades. Breast tomosynthesis is a relatively new digital x-ray mammography technique that produces multiple image slices of the breast similar to, but distinct from, computed tomography (CT). Xeromammography and galactography are somewhat outdated technologies that also use x-ray technology and are now used infrequently in the detection of breast cancer. Breast ultrasound is another technology employed in diagnosis and screening that can help differentiate between fluid filled and solid lesions, an important factor to determine if a lesion may be cancerous. Breast MRI is a technology typically reserved for high-risk patients and patients recently diagnosed with breast cancer. Lastly, scintimammography is used in a subgroup of patients who have abnormal mammograms or whose screening is not reliable on the basis of using traditional mammography or ultrasound.

HB 2102, also known as "Henda's Law", is a breast density (BD) notification law approved in 2011 by the FDA that mammography patients be provided educational materials on dense breast tissue can hide abnormalities, including breast cancer, from traditional screening. Henda's Law aims to promote patient–doctor discussion as well as reduce the rate of false negatives, as mammography may not detect abnormalities in dense breasts.

Dense breast tissue, also known as dense breasts, is a condition of the breasts where a higher proportion of the breasts are made up of glandular tissue and fibrous tissue than fatty tissue. Around 40–50% of women have dense breast tissue and one of the main medical components of the condition is that mammograms are unable to differentiate tumorous tissue from the surrounding dense tissue. This increases the risk of late diagnosis of breast cancer in women with dense breast tissue. Additionally, women with such tissue have a higher likelihood of developing breast cancer in general, though the reasons for this are poorly understood.

References

  1. 1 2 3 4 Kösters JP, Gøtzsche PC (2003). Kösters JP (ed.). "Regular self-examination or clinical examination for early detection of breast cancer". The Cochrane Database of Systematic Reviews. 2010 (2): CD003373. doi:10.1002/14651858.CD003373. PMC   7387360 . PMID   12804462.
  2. 1 2 Siu AL (February 2016). "Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement". Annals of Internal Medicine. 164 (4): 279–96. doi: 10.7326/M15-2886 . PMID   26757170.
  3. 1 2 3 4 5 6 7 8 9 10 Gøtzsche PC, Jørgensen KJ (June 2013). "Screening for breast cancer with mammography". The Cochrane Database of Systematic Reviews. 2013 (6): CD001877. doi:10.1002/14651858.CD001877.pub5. PMC   6464778 . PMID   23737396.
  4. ↑ "Guidelines". www.acraccreditation.org. Archived from the original on 26 July 2024. Retrieved 22 February 2021.
  5. ↑ Schonberg M. Breast cancer screening: at what age to stop? Archived 2011-10-04 at the Wayback Machine Consultant. 2010;50(May):196-205.
  6. 1 2 3 4 "Improving cancer screening in the European Union". 2 March 2022. Archived from the original on 2022-03-01. Retrieved 10 March 2022.
  7. ↑ Saslow D, Hannan J, Osuch J, Alciati MH, Baines C, Barton M, Bobo JK, Coleman C, Dolan M, Gaumer G, Kopans D, Kutner S, Lane DS, Lawson H, Meissner H, Moorman C, Pennypacker H, Pierce P, Sciandra E, Smith R, Coates R (2004). "Clinical breast examination: practical recommendations for optimizing performance and reporting". CA: A Cancer Journal for Clinicians. 54 (6): 327–44. doi: 10.3322/canjclin.54.6.327 . PMID   15537576.
  8. ↑ "Archived copy". Archived from the original on 2024-03-27. Retrieved 2024-03-27.{{cite web}}: CS1 maint: archived copy as title (link)
  9. ↑ "Archived copy". Archived from the original on 2024-03-27. Retrieved 2024-03-27.{{cite web}}: CS1 maint: archived copy as title (link)
  10. ↑ "Mammography". medlineplus.gov. Archived from the original on 2016-07-05. Retrieved 2021-03-31.
  11. 1 2 The Mayo Clinic Breast Cancer Book. RosettaBooks. 2012-11-16. p. 124. ISBN   9780795334306.[ permanent dead link ]
  12. ↑ Reynolds H (2012-08-07). The Big Squeeze: a social and political history of the controversial mammogram. Cornell University Press. p. 77. ISBN   978-0801465567.
  13. ↑ Croswell JM, Kramer BS, Kreimer AR, Prorok PC, Xu JL, Baker SG, Fagerstrom R, Riley TL, Clapp JD, Berg CD, Gohagan JK, Andriole GL, Chia D, Church TR, Crawford ED, Fouad MN, Gelmann EP, Lamerato L, Reding DJ, Schoen RE (2009). "Cumulative incidence of false-positive results in repeated, multimodal cancer screening". Annals of Family Medicine. 7 (3): 212–22. doi:10.1370/afm.942. PMC   2682972 . PMID   19433838.
  14. ↑ Smith-Bindman R, Ballard-Barbash R, Miglioretti DL, Patnick J, Kerlikowske K (2005). "Comparing the performance of mammography screening in the USA and the UK". Journal of Medical Screening . 12 (1): 50–4. doi:10.1258/0969141053279130. PMID   15814020. S2CID   20519761.
  15. ↑ Harris R, Yeatts J, Kinsinger L (September 2011). "Breast cancer screening for women ages 50 to 69 years a systematic review of observational evidence". Preventive Medicine. 53 (3): 108–14. doi:10.1016/j.ypmed.2011.07.004. PMID   21820465.
  16. 1 2 3 "Mammography-leaflet; Screening for breast cancer with mammography" (PDF). Archived from the original (PDF) on 2012-09-05. Retrieved 2012-06-24.
  17. ↑ Welch, H. Gilbert; Woloshin, Steve; Schwartz, Lisa A. (2011). Overdiagnosed: Making People Sick in the Pursuit of Health. Beacon Press. p. 149. ISBN   978-0-8070-2200-9.
  18. ↑ "Information on Mammography for Women Aged 40 and Older". 2010-01-05. Archived from the original on 2015-05-10. Retrieved 28 April 2015.
  19. 1 2 Nelson HD, Tyne K, Naik A, Bougatsos C, Chan BK, Humphrey L (November 2009). "Screening for breast cancer: an update for the U.S. Preventive Services Task Force". Annals of Internal Medicine. 151 (10): 727–37, W237–42. doi:10.7326/0003-4819-151-10-200911170-00009. PMC   2972726 . PMID   19920273.
  20. ↑ Armstrong K, Moye E, Williams S, Berlin JA, Reynolds EE (April 2007). "Screening mammography in women 40 to 49 years of age: a systematic review for the American College of Physicians". Annals of Internal Medicine. 146 (7): 516–26. doi: 10.7326/0003-4819-146-7-200704030-00008 . PMID   17404354.
  21. 1 2 US Preventive Services Task Force (November 2009). "Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement". Annals of Internal Medicine. 151 (10): 716–26, W–236. doi:10.7326/0003-4819-151-10-200911170-00008. PMID   19920272. Archived from the original on 2022-11-29. Retrieved 2022-04-04.
  22. ↑ "Why are women under 50 not routinely invited for breast screening?" Archived 2024-07-26 at the Wayback Machine , Public Health England, accessed 19 May 2014
  23. ↑ "Screening for breast cancer with mammography". cochrane.dk. Archived from the original on 2013-10-04. Retrieved 2013-05-06.
  24. ↑ Boyd NF, Martin LJ, Yaffe MJ, Minkin S (2011-11-01). "Mammographic density and breast cancer risk: current understanding and future prospects". Breast Cancer Research. 13 (6): 223. doi: 10.1186/bcr2942 . PMC   3326547 . PMID   22114898.
  25. ↑ Houssami N, Kerlikowske K (June 2012). "The Impact of Breast Density on Breast Cancer Risk and Breast Screening". Current Breast Cancer Reports. 4 (2): 161–168. doi:10.1007/s12609-012-0070-z. S2CID   71425894.
  26. ↑ Yaffe MJ (2008). "Mammographic density. Measurement of mammographic density". Breast Cancer Research. 10 (3): 209. doi: 10.1186/bcr2102 . PMC   2481498 . PMID   18598375.
  27. ↑ Sacchetto D, Morra L, Agliozzo S, Bernardi D, Björklund T, Brancato B, et al. (January 2016). "Mammographic density: Comparison of visual assessment with fully automatic calculation on a multivendor dataset". European Radiology. 26 (1): 175–183. arXiv: 1811.05324 . doi:10.1007/s00330-015-3784-2. PMID   25929945. S2CID   19841721.
  28. ↑ Fredenberg E, Berggren K, Bartels M, Erhard K (2016). "Volumetric Breast-Density Measurement Using Spectral Photon-Counting Tomosynthesis: First Clinical Results". In Tingberg A, Lång K, Timberg P (eds.). Breast Imaging. Lecture Notes in Computer Science. Vol. 9699. Cham: Springer International Publishing. pp. 576–584. arXiv: 2101.02758 . doi:10.1007/978-3-319-41546-8_72. ISBN   978-3-319-41545-1. S2CID   1257696 . Retrieved 2020-12-30.
  29. ↑ Ward E, Halpern M, Schrag N, Cokkinides V, DeSantis C, Bandi P, Siegel R, Stewart A, Jemal A (January–February 2008). "Association of insurance with cancer care utilization and outcomes". CA: A Cancer Journal for Clinicians. 58 (1): 9–31. doi: 10.3322/CA.2007.0011 . PMID   18096863. S2CID   24085070.
  30. ↑ Kaiser Family Foundation (December 31, 2006). "State Mandated Benefits: Cancer Screening for Women, 2006". Archived from the original on October 2, 2011.
  31. 1 2 "Organized Breast Cancer Screening Programs in Canada REPORT ON PROGRAM PERFORMANCE IN 2007 AND 2008" (PDF). cancerview.ca. Canadian Partnership Against Cancer. February 2013. Archived from the original (PDF) on April 21, 2016. Retrieved April 12, 2016.
  32. ↑ Canadian Cancer Society (April 2006). "Canadian Cancer Statistics, 2006" (PDF). Archived from the original (PDF) on 2007-07-29.
  33. ↑ The Information Centre (NHS) (March 23, 2007). "Breast Screening Programme 2005/06". Archived from the original on May 24, 2007. Retrieved December 20, 2007.
  34. ↑ Woodhead C, Cunningham R, Ashworth M, Barley E, Stewart RJ, Henderson MJ (October 2016). "Cervical and breast cancer screening uptake among women with serious mental illness: a data linkage study". BMC Cancer. 16 (1): 819. doi: 10.1186/s12885-016-2842-8 . PMC   5073417 . PMID   27769213.
  35. ↑ "Breast cancer screening: women with poor mental health are less likely to attend appointments". NIHR Evidence (Plain English summary). 2021-06-21. doi:10.3310/alert_46400. S2CID   241919707. Archived from the original on 2022-01-25. Retrieved 2022-04-04.
  36. ↑ Ross E, Maguire A, Donnelly M, Mairs A, Hall C, O'Reilly D (June 2020). "Does poor mental health explain socio-demographic gradients in breast cancer screening uptake? A population-based study". European Journal of Public Health. 30 (3): 396–401. doi: 10.1093/eurpub/ckz220 . PMID   31834366.
  37. ↑ "Cultural and language barriers need to be addressed for British-Pakistani women to benefit fully from breast screening". NIHR Evidence (Plain English summary). 2020-09-15. doi:10.3310/alert_41135. S2CID   241324844. Archived from the original on 2022-03-14. Retrieved 2022-04-04.
  38. ↑ Woof VG, Ruane H, Ulph F, French DP, Qureshi N, Khan N, et al. (September 2020). "Engagement barriers and service inequities in the NHS Breast Screening Programme: Views from British-Pakistani women". Journal of Medical Screening. 27 (3): 130–137. doi:10.1177/0969141319887405. PMC   7645618 . PMID   31791172.
  39. ↑ Woof VG, Ruane H, French DP, Ulph F, Qureshi N, Khan N, et al. (May 2020). "The introduction of risk stratified screening into the NHS breast screening Programme: views from British-Pakistani women". BMC Cancer. 20 (1): 452. doi: 10.1186/s12885-020-06959-2 . PMC   7240981 . PMID   32434564.
  40. ↑ "National Audit Office investigating NHS screening programmes". Health Service Journal. 24 October 2018. Archived from the original on 1 December 2018. Retrieved 1 December 2018.
  41. 1 2 "Women 'misjudge screening benefits'". BBC News. 15 October 2001. Archived from the original on 2003-04-25. Retrieved 2007-04-04.
  42. ↑ Welch, 2011. pp. 177–178.
  43. ↑ Shieh Y, Eklund M, Madlensky L, Sawyer SD, Thompson CK, Stover Fiscalini A, Ziv E, Van't Veer LJ, Esserman LJ, Tice JA (January 2017). "Breast Cancer Screening in the Precision Medicine Era: Risk-Based Screening in a Population-Based Trial". Journal of the National Cancer Institute. 109 (5): djw290. doi: 10.1093/jnci/djw290 . PMID   28130475.
  44. 1 2 "About the Breast Cancer Risk Assessment Calculator (The Gail Model)". National Cancer Institute. October 11, 2023. Archived from the original on October 30, 2023. Retrieved October 11, 2023.
  45. 1 2 O'Connor M, Rhodes D, Hruska C (August 2009). "Molecular breast imaging". Expert Review of Anticancer Therapy. 9 (8): 1073–80. doi:10.1586/era.09.75. PMC   2748346 . PMID   19671027.
  46. ↑ Moadel RM (May 2011). "Breast cancer imaging devices". Seminars in Nuclear Medicine. 41 (3): 229–41. doi:10.1053/j.semnuclmed.2010.12.005. PMID   21440698.
  47. ↑ O'Connor MK, Li H, Rhodes DJ, Hruska CB, Clancy CB, Vetter RJ (December 2010). "Comparison of radiation exposure and associated radiation-induced cancer risks from mammography and molecular imaging of the breast". Medical Physics. 37 (12): 6187–98. Bibcode:2010MedPh..37.6187O. doi:10.1118/1.3512759. PMC   2997811 . PMID   21302775.
  48. ↑ "Experimental and other breast imaging". American Cancer Society. Archived from the original on 13 December 2013. Retrieved 10 December 2013.
  49. ↑ Berg WA, Blume JD, Cormack JB, Mendelson EB, Lehrer D, Böhm-Vélez M, Pisano ED, Jong RA, Evans WP, Morton MJ, Mahoney MC, Larsen LH, Barr RG, Farria DM, Marques HS, Boparai K (May 2008). "Combined screening with ultrasound and mammography vs mammography alone in women at elevated risk of breast cancer". JAMA. 299 (18): 2151–63. doi:10.1001/jama.299.18.2151. PMC   2718688 . PMID   18477782. Review in: J Fam Pract. 2008 Aug;57(8):508 Archived 2017-11-23 at the Wayback Machine
  50. ↑ Berg WA, Zhang Z, Lehrer D, Jong RA, Pisano ED, Barr RG, Böhm-Vélez M, Mahoney MC, Evans WP, Larsen LH, Morton MJ, Mendelson EB, Farria DM, Cormack JB, Marques HS, Adams A, Yeh NM, Gabrielli G (April 2012). "Detection of breast cancer with addition of annual screening ultrasound or a single screening MRI to mammography in women with elevated breast cancer risk". JAMA. 307 (13): 1394–404. doi:10.1001/jama.2012.388. PMC   3891886 . PMID   22474203.
  51. 1 2 Hrung JM, Sonnad SS, Schwartz JS, Langlotz CP (July 1999). "Accuracy of MR imaging in the work-up of suspicious breast lesions: a diagnostic meta-analysis". Academic Radiology. 6 (7): 387–97. doi:10.1016/s1076-6332(99)80189-5. PMID   10410164.
  52. 1 2 Jochelson MS, Pinker K, Dershaw DD, Hughes M, Gibbons GF, Rahbar K, Robson ME, Mangino DA, Goldman D, Moskowitz CS, Morris EA, Sung JS (December 2017). "Comparison of screening CEDM and MRI for women at increased risk for breast cancer: A pilot study". European Journal of Radiology. 97: 37–43. doi:10.1016/j.ejrad.2017.10.001. PMID   29153365.
  53. ↑ "Breast MRI for Screening | Breastcancer.org". Breastcancer.org. Archived from the original on 2017-10-21. Retrieved 2017-10-23.
  54. ↑ Morrow M (December 2004). "Magnetic resonance imaging in breast cancer: one step forward, two steps back?". JAMA. 292 (22): 2779–80. doi:10.1001/jama.292.22.2779. PMID   15585740.
  55. ↑ "Ethnicity influences genetic risk scores for breast cancer". NIHR Evidence. 2022-03-28. doi:10.3310/alert_49859. S2CID   247830445. Archived from the original on 2022-08-05. Retrieved 2022-08-05.
  56. ↑ Evans DG, van Veen EM, Byers H, Roberts E, Howell A, Howell SJ, et al. (January 2022). "The importance of ethnicity: Are breast cancer polygenic risk scores ready for women who are not of White European origin?". International Journal of Cancer. 150 (1): 73–79. doi:10.1002/ijc.33782. PMC   9290473 . PMID   34460111.
  57. 1 2 3 "Genetic Risk Assessment and BRCA Mutation Testing for Breast and Ovarian Cancer Susceptibility: Recommendation Statement". Agency for Healthcare Research and Quality. United States Preventive Services Task Force. September 2005. Archived from the original on 2011-07-10. Retrieved 2011-03-07.
  58. ↑ "Breast Cancer Screening - Nipple Aspirate Test Is Not An Alternative To Mammography: FDA Safety Communication". Food and Drug Administration . Archived from the original on 16 September 2016. Retrieved 28 July 2016.
  59. ↑ "Nipple Aspirate Test is No Substitute for Mammogram". FDA. 2019-02-09. Archived from the original on 2018-03-09. Retrieved 2018-02-21.
  60. ↑ Godavarty A, Rodriguez S, Jung YJ, Gonzalez S (2015). "Optical imaging for breast cancer prescreening". Breast Cancer: Targets and Therapy. 7: 193–209. doi: 10.2147/BCTT.S51702 . PMC   4516032 . PMID   26229503.
  61. ↑ Harman, S. Mitchell; Gucciardo, Frank; Heward, Christopher B.; Granstrom, Per; Barclay-White, Belinda; Rogers, Lowell W.; Ibarra, Julio A. (October 2005). "Discrimination of breast cancer by anti-malignin antibody serum test in women undergoing biopsy". Cancer Epidemiology, Biomarkers & Prevention. 14 (10): 2310–2315. doi: 10.1158/1055-9965.EPI-04-0802 . ISSN   1055-9965. PMID   16214910. S2CID   9997137.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.